Prolactin disorders

Medicine

Volumn 37, Issue 8, 2009, Pages 411-413

  Martin, Niamh ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

bromocriptine; cabergoline; dopamine agonist; hyperprolactinaemia; prolactin; prolactinoma

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; CABERGOLINE; CIMETIDINE; CLOZAPINE; DOMPERIDONE; ESTROGEN; METOCLOPRAMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PHENOTHIAZINE DERIVATIVE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VERAPAMIL;

CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG CHOICE; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE INFERTILITY; GALACTORRHEA; HORMONE DETERMINATION; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; MENSTRUAL IRREGULARITY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PREGNANCY; PRIORITY JOURNAL; PROLACTINOMA; REVIEW; TUMOR REGRESSION; VALVULAR HEART DISEASE;

EID: 67749139968     PISSN: 13573039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mpmed.2009.05.003     Document Type: Review

References (15)

1. Karavitaki N., Thanabalasingham G., Shore H.C., et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol (Oxf) 65 (2006) 524-529
2. Chahal J., and Schlechte J. Hyperprolactinemia. Pituitary 11 (2008) 141-146
3. Casanueva F.F., Molitch M.E., Schlechte J.A., et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65 (2006) 265-273
4. Colao A., Di S.A., Cappabianca P., Di S.C., Pivonello R., and Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349 (2003) 2023-2033
5. Zanettini R., Antonini A., Gatto G., Gentile R., Tesei S., and Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356 (2007) 39-46
6. Schade R., Andersohn F., Suissa S., Haverkamp W., and Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356 (2007) 29-38
7. Wakil A., Rigby A.S., Clark A.L., Kallvikbacka-Bennett A., and Atkin S.L. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 159 (2008) R11-14
8. Colao A., Galderisi M., Di S.A., et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 93 (2008) 3777-3784
9. Bogazzi F., Buralli S., Manetti L., et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract 62 12 (2008) 1864-1869
10. Kars M., Delgado V., Holman E.R., et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 93 (2008) 3348-3356
11. Lancellotti P., Livadariu E., Markov M., et al. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 159 (2008) 1-5
12. Vallette S., Serri K., Rivera J., et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary (2008 July 2) [Epub ahead of print]
13. Kars M., Pereira A.M., Bax J.J., and Romijn J.A. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 159 (2008) 363-367
14. Krupp P., and Monka C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 65 (1987) 823-827
15. Colao A., Abs R., Barcena D.G., Chanson P., Paulus W., and Kleinberg D.L. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf) 68 (2008) 66-71